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licenseMetabolic syndrome and gastrointestinalehepatobiliary diseasesMetabolic syndrome (MS) is defined as a constellation of
clinical biological features closely related to insulin-
resistance, and has become a major public health challenge
worldwide. In Taiwan, the prevalence rate of MS is about
20%.1 Primary features of MS include elevated blood pressure,
dyslipidemia [increased triglycerides and reduced high-density
lipoprotein (HDL) cholesterol], raised fasting glucose, and
central obesity, as defined by the International Diabetes
Federation.2
People with MS have an increased risk of cardiovascular
diseases and Type 2 diabetes mellitus, and MS was also found
to be associated with several benign and malignant gastro-
intestinal (GI) and hepatobiliary diseases.
First, erosive esophagitis and Barrett's esophagus were
found to be strongly associated with MS in a cross-sectional
study.3 Old age, male, high body mass index (BMI), high
waist circumference, and triglyceride and low HDL were all
independent risk factors for predicting erosive esophagitis.4
Additionally, a large nationwide cohort study in Norway
showed that increased waist circumference was associated
with an increased hazard ratio of esophageal adenocarci-
noma.5 The increased risk in people with obesity partly
reflects the role of gastroesophageal reflux disease (GERD)
and Barrett’s esophagus in carcinogenesis; however, it is likely
that other factors such as inflammation, adipokines, and
insulin-like growth factor axis are also important.6
A systematic review and meta-analysis showed that Heli-
cobacter pylori infection is positively associated with MS
(higher triglyceride, fasting blood glucose, BMI, homeostatic
model assessment of insulin resistance, systemic blood pres-
sure, and lower HDL).7 One possible mechanism was that the
inflammatory conditions induced by chronic exposure to H.
pylori may influence the cytokine networks, including tumor
necrosis factor-a, interleukin-6, angiotensinogen, free fatty
acid, leptin, and adiponectin, which subsequently accelerates
abnormalities in metabolic parameters and finally leads to the
development of MS.7
Subjects with hypertension and MS were found to have a
significantly higher risk for subsequent adenoma or advanced
neoplasms, respectively, during surveillance colonoscopies.8,9
Colorectal cancer (CRC) risk is associated with high BMI,
with an estimated 3% increase in risk with each unit of BMI.10x.doi.org/10.1016/j.jcma.2016.09.002
901/Copyright © 2016, the Chinese Medical Association. Published by El
(http://creativecommons.org/licenses/by-nc-nd/4.0/).A systematic review and meta-analysis showed that MS is
associated with an increased risk of CRC incidence and
mortality.11 The plausible biological mechanisms to explain its
role in CRC risk include involvement of insulin resistance, as
well as acting as an energy depot for cancer cell growth which
may be mediated by dysregulation of growth signals, cyto-
kines and cellular crosstalk, and vascular integrity factors.
This further enables crosstalk between macrophages, adipo-
cytes, endothelial cells, and epithelial cells, and contributes to
cancer-related processes.11
A cross-sectional study in Japan found that irritable bowel
syndrome is significantly related to MS and elevated trigly-
ceride.12 There may be a link between visceral adiposity and
irritable bowel syndrome, but data about such a connection is
still limited.6 Recent findings also indicate similarities in
pathophysiological features between MS and inflammatory
bowel disease, including adipose tissue dysregulation, inad-
equate immune response, and inflammation.13
Regarding hepatobiliary pancreatic disease, high BMI,
central obesity, and MS increase the risk of gallstones.6,14
Prospective studies revealed that an increase in BMI and
impaired glucose metabolism pose a possible risk for gall-
bladder cancer and pancreatic cancer.6,15 Moreover, high BMI,
central obesity, MS, and Type 2 diabetes were noted to
increase the risk of nonalcoholic fatty liver disease, which can
progress to cirrhosis and ultimately hepatocellular carcinoma
(HCC).6,16 Although diabetes may be a surrogate for cirrhosis
due to glucose intolerance secondary to the development of
cirrhosis, which increases the risk of HCC, a prospective study
of 500,000 adults in North Europe showed that high BMI and
blood sugar were positively associated with a risk of primary
liver cancer.17
In conclusion, there are growing evidences suggesting that
MS increases the risk of nonmalignant GI disorders such as
GERD, nonalcoholic fatty liver disease, and gallstone, pre-
malignant GI disorders such as Barrett’s esophagus and colon
adenoma, and also increases the risk of GI malignancy
including esophageal adenocarcinoma, CRC, and gallbladder
cancer. However, further studies are needed to clarify the
possible mechanisms and the causal relationship between MS
and these GI tract disorders.sevier Taiwan LLC. This is an open access article under the CC BY-NC-ND
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